Skip to main content

Table 1 Baseline characteristics of the cohort

From: The predictive role of serum calprotectin on mortality in hemodialysis patients with high phosphoremia

 Total n = 388
Variablen (%), mean (±SD) or median (IQR)
Age, years65.3 (±12.6)
Female gender, n (%)143 (36.9)
Follow-up duration, years6.62 (3.76–6.64)
Vintage, years5.79 (2.93–12.12)
Systolic BP, mmHg146.7 (±20.3)
Diastolic BP, mmHg77.3 (±13.8)
BMI, kg/m221.7 (±3.5)
CTR, %49.0 (±5.3)
Single-pool Kt/V1.44 (±0.27)
ABI1.10 (0.99–1.17)
Smoking habits, n (%)64 (16.5)
RAS inhibitor, n (%)207 (53.3)
Statin, n (%)79 (20.4)
Chronic kidney disease etiology, n (%)
 Diabetic nephropathy136 (35.1)
 Hypertensive disease31 (8.0)
 Glomerulonephritis118 (30.4)
 Polycystic kidney disease10 (2.6)
 Others93 (24.0)
Comorbid conditions, n (%)
 Coronary artery disease (CAD)56 (14.4)
 Stroke64 (16.5)
 Peripheral Arterial Disease81 (20.9)
 Active cancer20 (5.2)
 Rheumatoid arthritis (RA)5 (1.3)
 Diabetes mellitus (DM)159 (41.0)
 Hypertension319 (82.2)
 Dyslipidemia198 (51.0)
Laboratory findings
 WBC, /μl5626 (±1666)
 hs-CRP, mg/l0.708 (0.295–1.828)
 Hemoglobin, g/dl10.7 (±1.1)
 Plt, 104/μl16.4 (±4.7)
 Albumin, g/dl3.8 (±0.33)
 BUN, mg/dl61.0 (±14.7)
 Cr, mg/dl10.9 (±2.6)
 Whole-PTH, pg/ml45 (24–92)
 aCa, mg/dl9.4 (±0.72)
 IP, mg/dl5.5 (±1.2)
 LDL-cholesterol, mg/dl79.3 (±23.6)
 TG, mg/dl84 (59–126)
 CPT, ng/ml6108 (4017–8906)
  1. SD standard deviation, IQR inter quartile range, BP blood pressure, BMI body mass index, CTR cardio-thoracic ratio, KT/V dialysis dose, ABI Ankle-Brachial-Index, Hb hemoglobin, Plt platelets, BUN blood urea nitrogen, Cr Creatinine, Whole-PTH whole parathyroid hormone, aCa adjusted calcium, IP inorganic phosphorus, LDL-Cho low density lipoprotein cholesterol, TG triglyceride, CPT calprotectin